141 related articles for article (PubMed ID: 36201194)
1. Outcomes After Treatment With Cobimetinib in Patients With Rosai-Dorfman Disease Based on KRAS and MEK Alteration Status.
Abeykoon JP; Rech KL; Young JR; Ravindran A; Ruan GJ; Dasari S; Morlote DM; King RL; Rummage C; Zanwar S; Acosta-Medina AM; Tobin WO; Shah MV; Bennani NN; Vassallo R; Ryu JH; Koster MJ; Davidge-Pitts CJ; Witzig TE; Goyal G; Go RS;
JAMA Oncol; 2022 Dec; 8(12):1816-1820. PubMed ID: 36201194
[TBL] [Abstract][Full Text] [Related]
2. Lung Involvement in Destombes-Rosai-Dorfman Disease: Clinical and Radiological Features and Response to the MEK Inhibitor Cobimetinib.
Moyon Q; Boussouar S; Maksud P; Emile JF; Charlotte F; Aladjidi N; Prévot G; Donadieu J; Amoura Z; Grenier P; Haroche J; Cohen Aubart F
Chest; 2020 Feb; 157(2):323-333. PubMed ID: 31669429
[TBL] [Abstract][Full Text] [Related]
3. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.
Shanmugam V; Margolskee E; Kluk M; Giorgadze T; Orazi A
Head Neck Pathol; 2016 Sep; 10(3):394-9. PubMed ID: 26922062
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis.
Aaroe A; Kurzrock R; Goyal G; Goodman AM; Patel H; Ruan G; Ulaner G; Young J; Li Z; Dustin D; Go RS; Diamond EL; Janku F
Blood Adv; 2023 Aug; 7(15):3984-3992. PubMed ID: 36857436
[TBL] [Abstract][Full Text] [Related]
5. Multiple Drug Regimen-Refractory Rosai-Dorfman-Destombes Disease Mimicking Relapsing Polychondritis Successfully Treated with Cobimetinib.
López-Aldabe K; Escrihuela-Vidal F; Tuells-Morales M; Llobera-Ris C; Bauer-Alonso A; Cortes-Romera M; Gràcia-Sànchez L; Tormo-Ratera M; Juanola Roura X; Penin-Mosquera RM; Corbella X; Solanich X
Eur J Case Rep Intern Med; 2022; 9(2):003076. PubMed ID: 35265540
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Shapiro GI; LoRusso P; Kwak E; Pandya S; Rudin CM; Kurkjian C; Cleary JM; Pilat MJ; Jones S; de Crespigny A; Fredrickson J; Musib L; Yan Y; Wongchenko M; Hsieh HJ; Gates MR; Chan IT; Bendell J
Invest New Drugs; 2020 Apr; 38(2):419-432. PubMed ID: 31020608
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.
Lieu CH; Hidalgo M; Berlin JD; Ko AH; Cervantes A; LoRusso P; Gerber DE; Eder JP; Eckhardt SG; Kapp AV; Tsuhako A; McCall B; Pirzkall A; Uyei A; Tabernero J
Oncologist; 2017 Sep; 22(9):1024-e89. PubMed ID: 28592615
[TBL] [Abstract][Full Text] [Related]
8. Investigating the correlation between small molecular inhibitor utilization, peripheral blood monocytes, and treatment outcomes in Rosai Dorfman disease.
Reynolds SB; Wilcox S; Li Q; Ahmed AZ
Ann Hematol; 2024 Jan; 103(1):37-59. PubMed ID: 37940718
[TBL] [Abstract][Full Text] [Related]
9. KRAS 117N positive Rosai-Dorfman disease with atypical features.
Jafri ZA; Reddy SP; Cassarino DS
J Cutan Pathol; 2021 Jan; 48(1):147-150. PubMed ID: 32974961
[TBL] [Abstract][Full Text] [Related]
10. Choroidal involvement in Rosai-Dorfman disease successfully treated with cobimetinib.
Giuffrè C; Giuffrè G
Indian J Ophthalmol; 2020 Sep; 68(9):2051-2053. PubMed ID: 32823478
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors.
Weekes C; Lockhart A; LoRusso P; Murray E; Park E; Tagen M; Singh J; Sarkar I; Mueller L; Dokainish H; Shapiro G; Burris H
Oncologist; 2020 Oct; 25(10):833-e1438. PubMed ID: 32311798
[TBL] [Abstract][Full Text] [Related]
12. Rosai-Dorfman-Destombes disease - histiocytic disorder with inflammatory manifestation.
Adam Z; Adamová Z; Pour L; Řehák Z; Koukalová R; Král Z
Klin Onkol; 2022; 35(4):262-170. PubMed ID: 35989082
[TBL] [Abstract][Full Text] [Related]
13. Recurrent central nervous system Rosai-Dorfman disease with KRAS mutation: a case report.
Wang Q; Ren H; Zheng L; Wang J; Zhong D
Diagn Pathol; 2023 Feb; 18(1):21. PubMed ID: 36782249
[TBL] [Abstract][Full Text] [Related]
14. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.
Garces S; Medeiros LJ; Patel KP; Li S; Pina-Oviedo S; Li J; Garces JC; Khoury JD; Yin CC
Mod Pathol; 2017 Oct; 30(10):1367-1377. PubMed ID: 28664935
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous Rosai-Dorfman disease with lack of BRAF-V600, KRAS or NRAS mutations: A reactive or neoplastic disorder?].
Machado I; Alcacer Fernández-Coronado J; Requena C; Través V; Latorre Martínez N; Ortega J; Requena L; Alcacer García J
Rev Esp Patol; 2022; 55(1):52-56. PubMed ID: 34980442
[TBL] [Abstract][Full Text] [Related]
16. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
17. Primary intraosseous Rosai-Dorfman disease: An analysis of clinicopathologic characteristics, molecular genetics, and prognostic features.
Weng X; Yang Y; Zhang M; Cai C; Sun Y; Wu X; Zhang R; Gui H; Li W; Xu Q; Liu X
Front Oncol; 2022; 12():950114. PubMed ID: 36185213
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients.
Wang KH; Chen WY; Liu HN; Huang CC; Lee WR; Hu CH
Br J Dermatol; 2006 Feb; 154(2):277-86. PubMed ID: 16433797
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of cases of Rosai Dorfman disease reported on the African continent and a description of two cases from a tertiary academic hospital in Johannesburg, South Africa.
Laudin GE; Lakha AB; Dullabh N; Mohanlal R; Jassat R; Waja MF; Philip V
Pan Afr Med J; 2023; 45():130. PubMed ID: 37790150
[TBL] [Abstract][Full Text] [Related]
20. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
Brufsky A; Kim SB; Zvirbule Ž; Eniu A; Mebis J; Sohn JH; Wongchenko M; Chohan S; Amin R; Yan Y; McNally V; Miles D; Loi S
Ann Oncol; 2021 May; 32(5):652-660. PubMed ID: 33539944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
